Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(24):1829; doi:10.1093/jnci/93.24.1829
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 93, No. 24, 1829, December 19, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Possible Mechanism for Resistance to Herceptin

Trastuzumab (Herceptin), a monoclonal antibody against the HER2/neu receptor, inhibits the growth of ErbB2-overexpressing breast cancer cells. Many patients with such breast cancers treated with trastuzumab will eventually develop resistance to the drug. Lu et al. (p. 1852) investigated the association of trastuzumab resistance and signaling via the insulin-like growth factor-I receptor (IGF-IR) by use of various human breast cancer cell lines. They found that trastuzumab inhibited growth of breast cancer cells overexpressing HER2/neu receptors only when IGF-IR signaling was minimized. . . . [Full Text of this Article]

Sonic Hedgehog Gene and Hair Growth After Chemotherapy

HPV16-E7 Oncoprotein and Cervical Endothelial Cells

Characteristics of Patients and Initial Prostate Cancer Therapy

Tomato Sauce Intervention for Prostate Cancer Patients

Hypoxia-Induced Drug Resistance and Nitric Oxide